Abstract:LINC01126 is highly expressed in castration‐resistant prostate cancer and is correlated with poor prognosis. AR‐targeted therapies upregulate LINC01126 expression through relieving its transcriptional repression by AR. LINC01126 facilitates the activation of AR signalling independent of androgen. LINC01126 promotes the transition from O‐GlcNAcylation at threonine 80 to phosphorylation at S81 within the AR protein. AR‐targeted therapies inhibit synthesis of AR ligand or block binding of AR ligand to AR. Without AR ligand, AR protein is O‐GlcNAcylated at threonine 80 and degrades rapidly. LINC01126 is transcriptionally repressed by AR. AR‐targeted therapies thereby upregulate LINC01126 expression through relieving its transcriptional repression by AR. LINC01126 facilitates the interaction of AR with CDK9, resulting in AR S81 phosphorylation. Consequences of AR S81 phosphorylation are analogous to the effect of androgen on AR stability, nuclear translocation and transactivation. Therefore, LINC01126 facilitates the activation of AR signalling independent of androgen, contributing to progression of CRPC. LINC01126‐ASO that specifically interferes the binding of AR to CDK9 may have a possible therapeutic effect on CRPC. Background Prostate cancer (PCa) initially shows satisfactory response to therapies targeting the androgen receptor (AR). However, progression to a castration‐resistant stage indicates poor prognosis in PCa patients. AR signalling still plays a central role in most castration‐resistant prostate cancers (CRPC). Therefore, unveiling the mechanisms of AR reactivation under androgen‐deprived conditions is imperative to discover novel therapeutic targets for CRPC. Methods Using an integrative analysis of the transcriptomics of three independent PCa cohorts and a published landscape of AR‐regulated long non‐coding RNA (lncRNA), lncRNA LINC01126 was selected as a candidate gene that could drive CRPC progression for further study. Quantitative reverse transcription polymerase chain reaction, in situ hybridisation (ISH) and fluorescent ISH were performed to detect LINC01126 in PCa tissues and cells. The functional role and mechanism of LINC01126 were further investigated using in vitro and in vivo gain and loss of function assays. Results LINC01126, identified as an AR‐repressed lncRNA, was significantly upregulated after AR‐targeted therapies. In addition, we found that LINC01126 was upregulated in CRPC and was associated with poor prognosis. We also proved that LINC01126 stabilised AR protein and enhanced AR nuclear translocation and transactivation by promoting the transition from O‐GlcNAcylation at threonine 80 to phosphorylation at serine 81 (S81) within the AR protein. Mechanism analysis revealed that LINC01126 facilitates the interaction of CDK9 with AR and impedes the binding of O‐linked N‐acetylglucosamine (O‐GlcNAc) transferase to AR. Consequently, LINC01126 expression was sufficient to activate AR signalling without androgen. LINC01126 overexpression increased, whereas LINC01126 knockdown decreased castration resistance traits in PCa cells in vitro and in vivo. Furthermore, our data showed that LINC01126‐targeting antisense oligonucleotides (ASO) substantially inhibited CRPC cells in vitro. Conclusions Our research expands the functions of AR‐regulated lncRNA in sustaining androgen‐independent AR activity and promoting CRPC progression and reveals that LINC01126 may be a new therapeutic target for PCa.

Androgen-responsive lncRNA LINC00304 promotes cell cycle and proliferation via regulating CCNA1.

Expression of lncRNA PCGEM1 and AR co-localization in prostate cancer and tis signiifcance

Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer.

Linc00963: A Novel, Long Non-Coding Rna Involved In The Transition Of Prostate Cancer From Androgen-Dependence To Androgen-Independence

[Expression of long noncoding RNA LINC01358 in prostate cancer and its effect on the proliferation and migration of prostate cancer cells].

[Long Noncoding RNA Linc00662 Promotes the Tumorigenesis of Prostate Cancer Cells].

LINC00675 Activates Androgen Receptor Axis Signaling Pathway to Promote Castration-Resistant Prostate Cancer Progression

Androgen‐repressed lncRNA LINC01126 drives castration‐resistant prostate cancer by regulating the switch between O‐GlcNAcylation and phosphorylation of androgen receptor

LncRNA MCM3AP-AS1 Promotes Cell Proliferation and Invasion Through Regulating Mir-543-3p/slc39a10/pten Axis in Prostate Cancer.

Long Intergenic Non-Protein Coding RNA 00342 Exerts Oncogenic Effects in Prostate Cancer by Sponging microRNA-19b-3p and Thereby Increasing Forkhead Box F2 Expression

Identification of androgen response‐related lncRNAs in prostate cancer

LINC00689 Promotes Prostate Cancer Progression Via Regulating Mir-496/Ctnnb1 to Activate Wnt Pathway

Long Non-coding RNAs LINC01679 as a Competitive Endogenous RNAs Inhibits the Development and Progression of Prostate Cancer via Regulating the miR-3150a-3p/SLC17A9 Axis

LINC00624/TEX10/NF-KB Axis Promotes Proliferation and Migration of Human Prostate Cancer Cells

Upregulation Of Long Noncoding Rna Loc440040 Promotes Tumor Progression And Predicts Poor Prognosis In Patients With Prostate Cancer

Comprehensive Characterization of Androgen-Responsive Lncrnas Mediated Regulatory Network in Hormone-Related Cancers.

STAT3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression

LINC01518 predicts poor prognosis of prostate cancer and promotes its progression by regulating hsa-miR-320a/CNKSR2 axis

Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis.

The Prostate Cancer-Up-regulated Long Noncoding RNA PlncRNA-1 Modulates Apoptosis and Proliferation Through Reciprocal Regulation of Androgen Receptor.

LncRNA CCAT1 Promotes Prostate Cancer Cells Proliferation, Migration, and Invasion Through Regulation of Mir-490-3p/frat1 Axis.